LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4.

Qing, Yi; Li, Qian; Zhao, Ling-Yan; Shi, Ping; Shan, Jin-Lu; Zhang, Wei.

Afiliación

Qing Y; Department of Oncology, Affiliated Hospital of Chengdu University, Chengdu 610081, People's Republic of China.
Li Q; Department of Oncology, Daping hospital, Army Medical University, Chongqing, 400042, China.
Zhao LY; Department of respiratory and critical care medicine, Guangyuan Central Hospital, Guangyuan City, Sichuan Province, 628000, China.
Shi P; Department of respiratory and critical care medicine, Guangyuan Central Hospital, Guangyuan City, Sichuan Province, 628000, China.
Shan JL; Department of Oncology, Daping hospital, Army Medical University, Chongqing, 400042, China.
Zhang W; Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China.

J Cancer ; 12(19): 5879-5887, 2021.

Article en En | MEDLINE | ID: mdl-34476001